Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredients in Maymetsi, are a biguanide and a DPP‑4 inhibitor presented as a tablet for oral use. They work together to lower hepatic glucose production, increase peripheral insulin sensitivity, and enhance glucose‑dependent insulin secretion, providing comprehensive glycaemic management for adults diagnosed with type 2 diabetes mellitus.

GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to stringent quality standards and regulatory requirements. The company serves hospitals, pharmacies, and clinics worldwide, offering reliable sourcing, consistent product availability, and comprehensive logistical support for global healthcare providers.

Maymetsi is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.

- Type 2 diabetes mellitus (initial therapy): used as first‑line treatment together with diet and exercise to achieve target HbA1c. - Type 2 diabetes mellitus (add‑on therapy): combined with other oral antidiabetics when monotherapy does not achieve glycaemic goals. - Type 2 diabetes mellitus (fixed‑dose combination): provides a convenient single tablet that delivers both metformin and sitagliptin for patients requiring dual mechanisms.

Maymetsi may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory tract symptoms: nasopharyngitis or cough. - Hypoglycaemia (when combined with insulin or sulfonylureas): mild episodes of low blood sugar.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

Prior to initiating Maymetsi, clinicians should evaluate patient-specific factors and monitor for potential risks.

- Renal function assessment: ensure adequate glomerular filtration rate before prescribing. - Hepatic impairment: use with caution in patients with liver disease. - Alcohol consumption: advise patients to limit alcohol to reduce lactic acidosis risk. - Concomitant hypoglycaemic agents: monitor blood glucose when used with insulin or sulfonylureas. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Maymetsi can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate metformin‑associated lactic acidosis; discontinue metformin before and after imaging. - Cimetidine: can increase metformin plasma concentrations. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise sitagliptin levels.

Moderate Interactions (Monitor Closely): - Sulfonylureas: increased risk of hypoglycaemia when combined. - Diuretics (thiazides): may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium. - NSAIDs: can reduce renal perfusion, enhancing metformin accumulation.